Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.
If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com
For other Takeda news releases, please visit the Takeda.com Newsroom.
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
Phase 3 Trial of NINLARO(TM) (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
